Temporal trends in the incidence of multiple sclerosis: A systematic review, Neurology, vol.71, issue.2, pp.129-135, 2008. ,
DOI : 10.1212/01.wnl.0000316802.35974.34
Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients, Multiple Sclerosis Journal, vol.17, issue.5, pp.595-601, 2008. ,
DOI : 10.1177/1352458507086425
Environmental risk factors for multiple sclerosis. Part I: The role of infection, Annals of Neurology, vol.66, issue.suppl, pp.288-299, 2007. ,
DOI : 10.1002/ana.21117
Critères diagnostiques de la sclérose en plaques : l'IRM et la clinique, Neurologies, vol.144, issue.15, pp.18-26, 2012. ,
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis, Brain, vol.120, issue.11, pp.2059-2069, 1997. ,
DOI : 10.1093/brain/120.11.2059
An Inventory for Measuring Depression, Archives of General Psychiatry, vol.4, issue.6, pp.561-571, 1961. ,
DOI : 10.1001/archpsyc.1961.01710120031004
??tude psychometrique du questionnaire de d??pression de Beck aupr??s d'un ??chantillon d'??tudiants universitaires francophones., Canadian Journal of Behavioural Science/Revue canadienne des sciences du comportement, vol.14, issue.3, pp.211-218, 1982. ,
DOI : 10.1037/h0081254
Physiopathologie de la scl??rose en plaques, La Presse M??dicale, vol.39, issue.3, pp.341-348, 2010. ,
DOI : 10.1016/j.lpm.2009.12.001
Place de l???EDSS dans l?????valuation pr??coce du handicap, Revue Neurologique, vol.165, pp.173-179, 2009. ,
DOI : 10.1016/S0035-3787(09)72131-9
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up, Arch. Neurol, vol.65, pp.727-732, 2008. ,
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis, Cochrane Database Syst Rev, p.6921, 2009. ,
Environmental changes and epidemiology of multiple sclerosis in the French West Indies, Journal of the Neurological Sciences, vol.286, issue.1-2, pp.58-61, 2009. ,
DOI : 10.1016/j.jns.2009.04.039
Multiple sclerosis: a geographical hypothesis, Medical Hypotheses, vol.49, issue.6, pp.477-486, 1997. ,
DOI : 10.1016/S0306-9877(97)90065-7
MRI only conversion to multiple sclerosis following a clinically isolated syndrome, Journal of Neurology, Neurosurgery & Psychiatry, vol.82, issue.2, pp.176-179, 2011. ,
DOI : 10.1136/jnnp.2010.208660
Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis, Current Medical Research and Opinion, vol.25, issue.6, pp.1445-1454, 2009. ,
DOI : 10.1185/03007990902876040
La qualit?? de vie des patients souffrant de scl??rose en plaques, Revue Neurologique, vol.165, issue.4, pp.123-128, 2009. ,
DOI : 10.1016/S0035-3787(09)72123-X
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N. Engl. J. Med, vol.362, pp.402-415, 2010. ,
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, The Lancet, vol.357, issue.9268, pp.1576-1582, 2001. ,
DOI : 10.1016/S0140-6736(00)04725-5
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial, The Lancet, vol.374, issue.9700, pp.1503-1511, 2009. ,
DOI : 10.1016/S0140-6736(09)61259-9
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial, Lancet Neurol, vol.11, pp.33-41, 2012. ,
Multiple sclerosis, Lancet, vol.359, pp.1221-1231, 2002. ,
Multiple sclerosis, Lancet, vol.372, pp.1502-1517, 2008. ,
Natural history of multiple sclerosis: a unifying concept, Brain, vol.129, issue.3, pp.606-616, 2006. ,
DOI : 10.1093/brain/awl007
Handicap social des formes pr??coces de scl??rose en plaques, Revue Neurologique, vol.165, pp.167-172, 2009. ,
DOI : 10.1016/S0035-3787(09)72130-7
Review: Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training, Multiple Sclerosis Journal, vol.29, issue.1, pp.35-53, 2008. ,
DOI : 10.1191/1352458503ms904oa
Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis, Journal of Neurology, Neurosurgery & Psychiatry, vol.63, issue.5, pp.565-568, 1997. ,
DOI : 10.1136/jnnp.63.5.565
Randomised double-blind placebo-controlled study of interferon ??-1a in relapsing/remitting multiple sclerosis, The Lancet, vol.352, issue.9139, pp.1498-1504, 1998. ,
DOI : 10.1016/S0140-6736(98)03334-0
Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies., Journal of Neurology, Neurosurgery & Psychiatry, vol.53, issue.10, pp.906-911, 1990. ,
DOI : 10.1136/jnnp.53.10.906
Caregiver's burden of patients 3 years after stroke assessed by a novel caregiver burden scale, Archives of Physical Medicine and Rehabilitation, vol.77, issue.2, pp.177-182, 1996. ,
DOI : 10.1016/S0003-9993(96)90164-1
Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires, Mult. Scler, vol.17, pp.1238-1249, 2011. ,
HHV-6 and multiple sclerosis, Nature Medicine, vol.171, issue.5, pp.537-538, 1998. ,
DOI : 10.1016/0166-0934(95)01983-9
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, vol.131, issue.3, pp.808-817, 2008. ,
DOI : 10.1093/brain/awm329
The effect of multiple sclerosis on the professional life of a group of Brazilian patients, Arquivos de Neuro-Psiquiatria, vol.68, issue.6, pp.914-917, 2010. ,
DOI : 10.1590/S0004-282X2010000600016
??pid??miologie de la scl??rose en plaques??: la particularit?? fran??aise, Revue Neurologique, vol.165, issue.8-9, pp.671-675, 2009. ,
DOI : 10.1016/j.neurol.2009.04.003
National estimate of multiple sclerosis incidence in France (2001???2007), Multiple Sclerosis Journal, vol.1210, issue.8, pp.1108-1115, 2001. ,
DOI : 10.3917/pope.701.0139
Geographic variations of multiple sclerosis in France, Brain, vol.133, pp.1889-1899, 2010. ,
Corticosteroids for treating optic neuritis, Cochrane Database Syst Rev, vol.4, p.1430, 2012. ,
Physical training and??multiple sclerosis, Annales de R??adaptation et de M??decine Physique, vol.50, issue.6, pp.373-376, 2007. ,
DOI : 10.1016/j.annrmp.2007.04.004
Cost-Effectiveness Analyses of Natalizumab (Tysabri??) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK, PharmacoEconomics, vol.71, issue.4, pp.617-627, 2008. ,
DOI : 10.2165/00019053-200826070-00008
Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS, Neurology, vol.78, issue.18, pp.1390-1393, 2012. ,
DOI : 10.1212/WNL.0b013e318253d61e
Anti-JC virus antibodies: Implications for PML Risk Stratification, Annals of Neurology, vol.361, issue.suppl, pp.295-303, 2010. ,
DOI : 10.1002/ana.22128
Validation of the MOS-HIV as a measure of health-related quality of life in persons living with HIV and liver disease, AIDS Care, vol.22, issue.4, pp.483-490, 2010. ,
DOI : 10.1080/09540120903207292
Drug Insight: using monoclonal antibodies to treat multiple sclerosis, Nature Clinical Practice Neurology, vol.64, issue.1, pp.34-44, 2005. ,
DOI : 10.1016/S0167-5699(00)01680-7
URL : http://hdl.handle.net/11858/00-001M-0000-0012-2253-1
The Multiple Sclerosis Work Difficulties Questionnaire, Multiple Sclerosis Journal, vol.12, issue.6, pp.871-880, 2012. ,
DOI : 10.1016/j.jns.2005.08.019
Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis, New England Journal of Medicine, vol.343, issue.13, pp.898-904, 2000. ,
DOI : 10.1056/NEJM200009283431301
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis, Annals of Neurology, vol.43, issue.3, pp.285-294, 1996. ,
DOI : 10.1002/ana.410390304
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial, Neurology, vol.45, issue.7, pp.1268-1276, 1995. ,
DOI : 10.1212/WNL.45.7.1268
Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline, Clinical Neuropharmacology, vol.35, issue.2, pp.77-80, 2012. ,
DOI : 10.1097/WNF.0b013e31824644e6
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, issue.7, pp.1242-1249, 2006. ,
DOI : 10.1212/01.wnl.0000237641.33768.8d
A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis, N. Engl. J. Med, vol.362, pp.387-401, 2010. ,
A Measure of Primary Sociobiological Functions, International Journal of Health Services, vol.2, issue.1, pp.493-508, 1976. ,
DOI : 10.1093/geront/10.1_Part_1.20
Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab, Journal of Neuropathology & Experimental Neurology, vol.71, issue.7, pp.604-617, 2012. ,
DOI : 10.1097/NEN.0b013e31825caf2c
Conclusions:, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, vol.17, issue.03, pp.422-428, 2011. ,
DOI : 10.1002/ana.410390304
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1452, 1983. ,
DOI : 10.1212/WNL.33.11.1444
The effects of clinical interventions on health-related quality of life in multiple sclerosis: a meta-analysis, Multiple Sclerosis Journal, vol.25, issue.12, pp.1-19, 2012. ,
DOI : 10.1016/j.jclinepi.2009.03.020
Cortical demyelination and diffuse white matter injury in multiple sclerosis, Brain, vol.128, issue.11, pp.2705-2712, 2005. ,
DOI : 10.1093/brain/awh641
Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis, Archives of Neurology, vol.63, issue.12, pp.1686-1691, 2006. ,
DOI : 10.1001/archneur.63.12.1686
ASSESSMENT OF OLDER PEOPLE, Nursing Research, vol.19, issue.3, pp.179-186, 1969. ,
DOI : 10.1097/00006199-197005000-00029
MULTIPLE SCLEROSIS IN IMMIGRANT AND NATIVE POPULATIONS OF ISRAEL, The Lancet, vol.294, issue.7634, pp.1323-1325, 1969. ,
DOI : 10.1016/S0140-6736(69)90863-0
Neurophysiological markers, Neurological Sciences, vol.124, issue.[Suppl1], pp.218-221, 2008. ,
DOI : 10.1007/s10072-008-0942-1
Evidence for a two-stage disability progression in multiple sclerosis, Brain, vol.133, issue.7, pp.1900-1913, 2010. ,
DOI : 10.1093/brain/awq076
Defining the clinical course of multiple sclerosis: Results of an international survey, Neurology, vol.46, issue.4, pp.907-911, 1996. ,
DOI : 10.1212/WNL.46.4.907
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies, Annual Review of Medicine, vol.61, issue.1, pp.35-47, 2010. ,
DOI : 10.1146/annurev.med.080708.082655
Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6, Journal of General Virology, vol.88, issue.1, pp.264-274, 2007. ,
DOI : 10.1099/vir.0.81890-0
Environmental risk factors in multiple sclerosis aetiology, The Lancet Neurology, vol.3, issue.12, pp.709-718, 2004. ,
DOI : 10.1016/S1474-4422(04)00933-0
Mitoxantrone for multiple sclerosis, Cochrane Database Syst Rev, p.2127, 2005. ,
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis, Annals of Neurology, vol.70, issue.1, pp.121-127, 2001. ,
DOI : 10.1002/ana.1032
Screening for the risk of job loss in multiple sclerosis (MS): development of an MS-specific Work Instability Scale (MS-WIS), Multiple Sclerosis Journal, vol.6, issue.6, pp.862-870, 2012. ,
DOI : 10.1002/acr.20272
The MOS 36-Item Short-Form Health Survey (SF-36), Medical Care, vol.31, issue.3, pp.247-263, 1993. ,
DOI : 10.1097/00005650-199303000-00006
PAST SUN EXPOSURE, SKIN PHENOTYPE AND RISK OF MULTIPLE SCLEROSIS, Epidemiology, vol.14, issue.Supplement, p.316, 2003. ,
DOI : 10.1097/00001648-200309001-00275
Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis, Journal of Neurology, vol.256, issue.Suppl 3, pp.1215-1221, 2012. ,
DOI : 10.1007/s00415-011-6339-8
A controlled trial of natalizumab for relapsing multiple sclerosis, N. Engl. J. Med, vol.348, pp.15-23, 2003. ,
Corticosteroids in the treatment of multiple sclerosis, Acta Neurologica Scandinavica, vol.16, pp.73-80, 2009. ,
DOI : 10.1111/j.1600-0404.2009.01213.x
Multiple Sclerosis, New England Journal of Medicine, vol.343, issue.13, pp.938-952, 2000. ,
DOI : 10.1056/NEJM200009283431307
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study, European Journal of Neurology, vol.14, issue.3, pp.420-423, 2009. ,
DOI : 10.1111/j.1468-1331.2008.02517.x
Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice, J. Neurol, vol.257, pp.207-211, 2010. ,
Traitements actuels de la scl??rose en plaques, La Presse M??dicale, vol.39, issue.3, pp.381-388, 2010. ,
DOI : 10.1016/j.lpm.2009.05.021
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci, Annals of Neurology, vol.10, issue.6, pp.897-912, 2011. ,
DOI : 10.1002/ana.22609
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3247076
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, vol.43, issue.4, pp.662-667, 1993. ,
DOI : 10.1212/WNL.43.4.662
Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults, Journal of Clinical Epidemiology, vol.48, issue.8, pp.1051-1060, 1995. ,
DOI : 10.1016/0895-4356(94)00227-H
Social consequences of multiple sclerosis. Part 2. Divorce and separation: a historical prospective cohort study, Multiple Sclerosis Journal, vol.24, issue.7, pp.878-882, 2010. ,
DOI : 10.1093/brain/awh714
Social consequences of multiple sclerosis (1): early pension and temporary unemployment--a historical prospective cohort study, Mult. Scler, vol.16, pp.121-126, 2010. ,
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N. Engl. J. Med, vol.354, pp.899-910, 2006. ,
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann. Neurol, vol.69, pp.292-302, 2011. ,
Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria, Ann. Neurol, vol.58, pp.840-846, 2005. ,
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols, Annals of Neurology, vol.122, issue.3, pp.227-231, 1983. ,
DOI : 10.1002/ana.410130302
FP33-WE-02 Efficacy of natalizumab in second-line therapy of relapsing remitting multiple sclerosis: results from a multi-center study in German speaking countries, Journal of the Neurological Sciences, vol.285, pp.31-37, 2010. ,
DOI : 10.1016/S0022-510X(09)70440-X
Health-related quality of life in multiple sclerosis: effects of natalizumab, Ann. Neurol, vol.62, pp.335-346, 2007. ,
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, N. Engl. J. Med, vol.354, pp.911-923, 2006. ,
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab, Multiple Sclerosis Journal, vol.18, issue.2, pp.143-152, 2012. ,
DOI : 10.1177/1352458511435105
Potassium Channel KIR4.1 as an Immune Target in Multiple Sclerosis, New England Journal of Medicine, vol.367, issue.2, pp.115-123, 2012. ,
DOI : 10.1056/NEJMoa1110740
Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML), PLoS Genetics, vol.4, issue.10, p.1000368, 2009. ,
DOI : 10.1371/journal.pgen.1000368.s004
Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis, AJNR Am J Neuroradiol, vol.21, pp.702-706, 2000. ,
Imagerie par r??sonance magn??tique de l???inflammation du syst??me nerveux central, Revue Neurologique, vol.165, pp.77-87, 2009. ,
DOI : 10.1016/S0035-3787(09)73952-9
Axonal Transection in the Lesions of Multiple Sclerosis, New England Journal of Medicine, vol.338, issue.5, pp.278-285, 1998. ,
DOI : 10.1056/NEJM199801293380502
The immunology of multiple sclerosis: changing concepts], Rev. Neurol. (Paris), vol.164, issue.2, pp.138-146, 2008. ,
Quality of life and multiple sclerosis: validation of the french version of the self-questionnaire (SEP-59)], Rev. Neurol. (Paris), vol.156, pp.247-263, 2000. ,
A health-related quality of life measure for multiple sclerosis, Quality of Life Research, vol.30, issue.Suppl 1, pp.187-206, 1995. ,
DOI : 10.1007/BF02260859
Natural history of multiple sclerosis: risk factors and prognostic indicators, Current Opinion in Neurology, vol.20, issue.3, pp.269-274, 2007. ,
DOI : 10.1097/WCO.0b013e32812583ad
The Natural History of Multiple Sclerosis, Presse Med, vol.39, pp.359-362, 2010. ,
DOI : 10.1201/9780824741846.ch17
Twin concordance and sibling recurrence rates in multiple sclerosis, Proceedings of the National Academy of Sciences, vol.100, issue.22, pp.12877-12882, 2003. ,
DOI : 10.1073/pnas.1932604100
Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis [Internet] Multiple sclerosis (Houndmills, p.2012, 2012. ,
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis, Neurology, vol.67, issue.5, pp.804-808, 2006. ,
DOI : 10.1212/01.wnl.0000234064.17156.03
The prognostic value of age, gender, pregnancy and endocrine factors in multiple sclerosis, Neurological Sciences, vol.21, issue.0, pp.857-860, 2000. ,
DOI : 10.1007/s100720070026